Traders should monitor upcoming FDA engagement updates and the resolution of litigation; the significant cash burn and lack of near-term revenue raise solvency concerns despite reduced R&D spend.
Price Chart
Executive Summary
Filana Therapeutics reported a significantly wider net loss of $91.0 million in 2025 compared to $24.3 million in 2024, driven by the absence of a $108.1 million gain from warrant liabilities recorded in 2024. R&D expenses dropped 62% due to the discontinuation of its Alzheimer's program, and the company faces a $31.25 million estimated litigation settlement. Cash declined from $128.6 million to $95.5 million, with projected further drawdown to $47–$50 million by mid-2026.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $91.0 million ($1.88 per share), up from $24.3 million ($0.53 per share) in 2024.
- R&D expenses fell 62% to $26.6 million in 2025 due to the phase-out of the Alzheimer's program.
- Company expects to pay $31.25 million related to securities litigation settlement.
- Cash and cash equivalents decreased from $128.6 million (2024) to $95.5 million (2025), with projected cash of $47–$50 million by June 30, 2026.
- Clinical hold remains on simufilam for TSC-related epilepsy; FDA response pending additional data submission.
Financial Impact
Net loss increased by $66.7 million year-over-year; $31.25 million litigation payment expected in first half of 2026; cash burn projected at $45–$48 million over next six months including settlement.
Risk Factors
- Failure to resolve FDA clinical hold could delay or halt development of simufilam.
- Additional litigation or regulatory actions could further deplete cash reserves.
- High cash burn rate may necessitate dilutive financing if no partnerships or funding are secured.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254574 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6100 (−11.40%) |
Sep 22, 2026 4w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6100 (−40.78%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6100 (+17.51%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6100 (−29.85%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6100 (−49.59%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6100 (+55.15%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6100 (−55.15%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6100 (+68.72%) |
Mar 10, 2026 32w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6100 (−74.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers